Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTLA
CUSIPN/A
Phone857-285-6200
Debt
Debt-to-Equity RatioN/A
Current Ratio12.62
Quick Ratio12.62
Price-To-Earnings
Trailing P/E Ratio-14.76
Forward P/E Ratio-14.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.12 million
Price / Sales45.88
Cash FlowN/A
Price / CashN/A
Book Value$8.33 per share
Price / Book3.33
Profitability
EPS (Most Recent Fiscal Year)($1.88)
Net Income$-67,540,000.00
Net Margins-284.56%
Return on Equity-31.54%
Return on Assets-25.03%
Miscellaneous
Employees195
Outstanding Shares43,200,000
Market Cap$1.20 billion
Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions
What is Intellia Therapeutics' stock symbol?
Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."
How were Intellia Therapeutics' earnings last quarter?
Intellia Therapeutics Inc (NASDAQ:NTLA) issued its quarterly earnings results on Wednesday, August, 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.55) by $0.03. The business had revenue of $7.68 million for the quarter, compared to the consensus estimate of $6.39 million. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The firm's quarterly revenue was up 30.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.45) EPS. View Intellia Therapeutics' Earnings History.
When is Intellia Therapeutics' next earnings date?
What price target have analysts set for NTLA?
9 brokerages have issued 1 year price objectives for Intellia Therapeutics' shares. Their predictions range from $20.00 to $46.00. On average, they expect Intellia Therapeutics' stock price to reach $34.8333 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics.
What is the consensus analysts' recommendation for Intellia Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intellia Therapeutics.
What are Wall Street analysts saying about Intellia Therapeutics stock?
Here are some recent quotes from research analysts about Intellia Therapeutics stock:
- 1. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (8/7/2018)
- 2. Cann analysts commented, "Update highlights include advancement in ex vivo development and expectations for timing of first IND. Loss per share was $0.51 compared to our estimated loss of $0.44 This primarily was the result of higher R&D of $22.5 million compared to our estimate of $19.0 million; and was partially offset by higher than expected interest income. Our revenue outlook for 2018-22 remains unchanged. We are modestly decreasing our estimated shares outstanding in 2018-22; as a result, we are making very slight adjustments to our estimated loss per share in 2019-22." (5/1/2018)
Who are some of Intellia Therapeutics' key competitors?
Some companies that are related to Intellia Therapeutics include Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC) and Akers Biosciences (AKER).
Who are Intellia Therapeutics' key executives?
Intellia Therapeutics' management team includes the folowing people:
- Dr. John M. Leonard, Pres, CEO & Director (Age 61)
- Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 45)
- Mr. Graeme Bell, Exec. VP & CFO (Age 51)
- Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 52)
- Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 32)
When did Intellia Therapeutics IPO?
(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Has Intellia Therapeutics been receiving favorable news coverage?
News coverage about NTLA stock has trended positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intellia Therapeutics earned a news and rumor sentiment score of 0.32 on Accern's scale. They also assigned news headlines about the company an impact score of 44.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Intellia Therapeutics.
Who are Intellia Therapeutics' major shareholders?
Intellia Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.45%), BlackRock Inc. (5.92%), FMR LLC (5.85%), Morgan Stanley (5.17%), Atlas Venture Associates IX LLC (4.26%) and Orbimed Advisors LLC (2.03%). Company insiders that own Intellia Therapeutics stock include Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard, Nessan Bermingham and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.
Which major investors are selling Intellia Therapeutics stock?
NTLA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Atlas Venture Associates IX LLC, Baker BROS. Advisors LP, Orbimed Advisors LLC and Raymond James & Associates. Company insiders that have sold Intellia Therapeutics company stock in the last year include Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard and Nessan Bermingham. View Insider Buying and Selling for Intellia Therapeutics.
Which major investors are buying Intellia Therapeutics stock?
NTLA stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, BlackRock Inc., Morgan Stanley, Bank of America Corp DE, First Trust Advisors LP, Chevy Chase Trust Holdings Inc., Korea Investment CORP and Bank of New York Mellon Corp. View Insider Buying and Selling for Intellia Therapeutics.
How do I buy shares of Intellia Therapeutics?
Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intellia Therapeutics' stock price today?
One share of NTLA stock can currently be purchased for approximately $27.74.
How big of a company is Intellia Therapeutics?
Intellia Therapeutics has a market capitalization of $1.20 billion and generates $26.12 million in revenue each year. The company earns $-67,540,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Intellia Therapeutics employs 195 workers across the globe.
How can I contact Intellia Therapeutics?
Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at lindsey.tricke[email protected]
MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
